Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-02-22
2005-02-22
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S036000, C514S038000, C514S039000, C536S013600, C536S016800, C536S004100
Reexamination Certificate
active
06858589
ABSTRACT:
The invention provides a method of potentiating the activity of antibacterial agents that act on bacterial cell walls, comprising the step of administering to a subject an antibacterial agent and an aminoglycoside to attain a peak concentration of at least 4 mg/l of aminoglycoside and thereafter maintaining the aminoglycoside at a concentration of up to 4 mg/l for at least 1 hour. Compositions comprising an antibacterial agent and an aminoglycoside for efficacious treatment of bacterial infection are also provided.
REFERENCES:
patent: 3536809 (1970-10-01), Appleweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4710384 (1987-12-01), Rotman
patent: 5059595 (1991-10-01), Le Grazie
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5674533 (1997-10-01), Santus et al.
patent: 5733566 (1998-03-01), Lewis
patent: 6106858 (2000-08-01), Ye et al.
patent: 6475992 (2002-11-01), McLean
Weinstein et al., “Cephalosporin-Aminoglycoside Synergism in Experimental Enterococcal Endocarditis”, Antimicrobial Agents and Chemotherapy, Jun. 1976, p. 983-987.*
O'Kane, G.M., Gottlieb, T & Bradbury, R. (1998). Staphylococcal bacteraemia: the hospital or the Home? A review ofStaphylococcus aureusbacteraemia at Concord Hospital in 1993.Australia and New Zealand Journal of Medicine. 28, 23-27.
Rosenberg, J. (1995). Methicillin-resistantStaphylococcus auresus(MRSA) in the community: who's watching?The Lancet, 346, 132-133.
Pate, K.R., Nolan, R.L., Bannerman, R.I.& Feldman, S. (1995). Methicillin-resistantStaphylococcus aureusin the community.The Lancet, 346, 978.
Boyce, J.M.(1998). Are the epidermioligy and microbiology of methicillin-resistantStaphylococcus aureuschanging? JAMA, 279(8),623-624.
Herold, B.C. Immergluck, L.C., Maranan, M.C., Lauderdale, D.S., Gaskin, R.E., Boyle-Vavra, S., Leitch, C.D. and Daum, R.S. (1998). Community-acquired methicillin-resistantStaphylococcus aureusin children with no identified predisposing risk.Journal of the American Medical Association, 279(8), 593-598.
Lindenmayer, J.M., Schoenfeld, S. O'Grady, R. and Carney, J.K. (1998). Methicillin-resistantStaphylococcus aureusin a high school wrestling team and the surrounding community.Archives of Internal Medicine, 158, 895-899.
Moreno, F., Crisp, C., Jorgensen, J.H. & Patterson, J.E. (1995). Methicillin-resistantStaphylococcus aureusas a community organism.Clinical Infectious Diseases, 21, 1308-12.
Steinberg, J.P., Clark, C.C. and Hackman, B.O. (1996). Nosocomial and community-acquiredStaphylococcus aureusbacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance.Clinical Infectious Diseases, 23, 255-259.
Akram, J.& Glatt, A.E. (1998). True community-acquired methicillin-resistantStaphylococcus aureusbacteremia.Infection Control and Hospital Epidemiology, 19(2), 106-107.
Kayaba, H., Kodama, K., Tamura, H. & Fujiwara, Y. (1996). The spread of methicillin-resistant in a rural community: will it become a common microorganism colonizing among the general population?Surgery Today, 27, 217-219.
Mitchell, J.M. MacCulloch, D. & Morris, A.J. (1996). MRSA in the community.New Zealand Medical Journal, 109(1032), 411.
Maguire, G.P., Arthur, A.D., Boustead, P.J., Dwyer, B. & Currie, B.J. (1996). Emerging epidemic of community-acquired methicillin-resistantStaphylococcus aureusinfection in the Northern Territory.Medical Jouranl of Australia, 164, 721-723.
Riley, T.V., Pearman, J.W. and Rouse, I.L.(1995). Changing Epidemiology of methicillin-resistantStaphylococcus aureusin Western Australia.The Medical Journal of Australia, 163, 412-414.
Collignon, P., Gosbell, I., Vickery, A., Nimmo, G., Stylianopoulos, T., & Gottlieb, T (1998). Community-acquired methicillin-resistantStaphylococcus aureusin Australia.The Lancet, 352, 145-146.
Maguire, G.P., Arthur, A.D., Boustead, P.J., Dwyer, B. and Currie, B.J. (1998). Clinical experience and outcomes of community-acquired and nosocomial methicillin-resistantStaphylococcus aureusin a northern Australian hospital.Journal of Hospital Infections, 38, 273-281.
Daum, R.S. (1998). Community-acquired methicillin-resistantStaphylococcus aureusinfections.Concise Reviews of Pediatic Infectious Diseases, 17(8), 745-747.
Fogel, M.A., Nussbaum, P.B., Feintzeig, I.D. Hunt, W.A., Gavin, J.P. and Kim, R.C. (1998). Cephazolin in chronic hemodialysis patients: a safe, effective alternative to vancomycin.American Journal of Kidney Diseases, 32(3), 401-409.
Bastone, E.B., Li, S.C., Ioannides-Demos, L.L., Spicer, W.J. & McLean, A.J. (1993). Kill kinetics and regrowth patterns ofEschericia coliexposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing.Antimicrobial Agents and Chemotherapy, 37(4), 914-917.
Begg. E.J. & Barclay, M.L. (1995). Aminoglycosides- 50 years.British Journal of Clinical Pharmacology. 39, 597-603.
Wood, P.J., Ioannides-Demos, L.L., Bastone, E.B., Spicer, W.J. & McLean, A.J. (1996). Kill kinetics and regrowth patterns ofPseudomonas aeruginosaexposed to concentration-time profiles of tobramycin simulating in vivo infusion and bolus dosing.Antimicrobial Agents and Chemotherapy, 40(5), 1321-1324.
Ali, M.Z. & Goetz, M.B. (1997). A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides.Clionical Infectious Diseases24, 796-809.
Moore, R.D., Lietman, P.S.& Smith, C.R. (1987). Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.The Journal of Infectious Diseases, 155(1), 93-99.
Gerber, A.U,., Wiprachtiger, P., Stettler-Spichiger, U. & Lebek, G. (1982). Constant infusions vs. intermittent doses of gentamicin againstPseudomonas aeruginosain-vitro.The Journal of Infectious Diseases, 145(4), 554-560.
Rayner, C.R., Ioannides-Demos, L.L, Brien, J.E., Lioloios, L.L. & Spicer, W.J. (1998). Initial concentration-time profile of gentamicin determines efficacy againstEnterobacter cloacasATCC 13047.Antimicrobial Agents and Chemotherapy, 42(6), 1370-1374.
Ioannides-Demos, L.L., Liolios, L.L., Wood, P., Spicer, W.J. & McLean, A.J. (1998). Changes in MIC alter responses toPseudomonas aeruginoseto tobramycin exposure.Antimicrobial Agents and Chemotherapy, 42(6)1365-1369.
Ter Braak, E.W., De Vries, P.J., Boutler, K.P., Van Der Vegt, S.G., Dorrestein, G.C., Nortier, J.W., Van Dijk, A., Verkooyen, R.P. & Verbrugh, H.A. (1990). Once-daily dosing regimen for aminoglycoside plus β-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone.American Journal of Medicine, 89, 58-65.
Kapusnik, J.E., Hackbarth, C.J., Chambers, H.F., Carpenter, T & Sande, M.A. Single, larger, daily dosing versus ontermittent dosing of toramycin for treating experimentalPseudomonas pneumonia. Journal of Infectious Diseases, 158(1), 7-12, 1988.
Gavalda, J., Cardona, P.J., Almitrante, B., Capdevila, A.J., Laguarda, M., Pou, L., Crespo, E., Pigrau, C. & Pahissa, A. (1996). Treatment of experiemntal endocarditis due toEnterococcus faecalisusing once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin human serum.Antimicrobial Agents and Chemotherapy, 40(1), 173-178.
Bailey, R.R., Begg, E.J., Smith, A. H., Robson, R.A., Lynn, K.L., Chambers, S.T., Barclay, M.L. & Hornibrook, J. (1996). Prospective, randomized, controlled study comparing two dosing regimens of gentamicin/oral ciprofloxacin switch therapy for acute pyelonephritis.Clinical Nephrology, 46(3), 183-186.
Bailey, T.C., Little, J.R., Littenberg, B., Reichley, R.M. & Dunagan, W.C. (1997). A meta-analysis of extended-internal dosing versus multiple daily dosing of aminoglycosides.Clinical
McIntosh III Traviss C.
Pharmacy and Therapeutic Advisory Consultancy Pty LTD
Schulman B. Aaron
Stites & Harbison PLLC
Wilson James O.
LandOfFree
Methods of and compositions for potentiating the action of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of and compositions for potentiating the action of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of and compositions for potentiating the action of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3497675